CENTER ON BEHAVIORAL MEDICINE
Disease: Research Article
Bschor, Tl, Baethge, C., et al. (2003).
System Activity During Lithium Augmentation Therapy In Patients With
Major Depression. Journal of Psychiatry & Neuroscience;
Objective: Lithium augmentation is an established strategy in the treatment of refractory depression, but little is known about predictors of response and its mode of action. There is increasing evidence that low thyroid function indices within the normal range are associated with a poorer treatment response to antidepressants, but previous studies on the hypothalamic-pituitary-thyroid (HPT) system during lithium augmentation provide inconclusive results and have methodological limitations. This study aimed at exploring the role of thyroid function in lithium augmentation and used a prospective design that included a homogeneous sample of inpatients with unipolar major depressive disorder.
Methods: In 24 euthyroid patients with a major depressive episode who had not responded to antidepressant monotherapy of at least 4 weeks, we measured serum thyroid-stimulating hormone (TSH), total triiodothyronine (T,) and total thyroxine (Tq) before (baseline) and during lithium augmentation therapy (follow-up). The time point of the endocrinological follow-up depended on the status of response, which was assessed weekly with the Hamilton Depression Rating Scale, 17-item version (HDRS„). Responders were reassessed immediately after response was determined, and non-responders after 4 weeks of lithium augmentation.
Results: There was a statistically significant change in thyroid system activity during lithium augmentation, with an increase of TSH levels and a decrease of peripheral T, and T, levels. However, there were no differences in any of the HPT hormones between responders and non-responders at baseline or at follow-up.
Conclusions: The decrease of thyroid system activity during lithium treatment reflects the well-established "antithyroid" properties of lithium. However, it appears that thyroid status does not predict response to lithium augmentation in euthyroid patients before treatment.
1. de Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981;138:252-6.
2. Bauer M, Whybrow PC, Angst J, Versiani M, M611er HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatr 2002;3:5-43.
3. Joffe RT, Singer W, Levitt Al, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993,50:387-93.
4. Katona CLE, Abou-Saleh MT, Harrison DA, Nairac BA, Ed-wards DRL, Lock T, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995;166:80-6.
5. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychophannaco11996;16:307-14.
6. Bauer M, Bschor T, Kunz D, Bergh6fer A, Str6hle A, Miiller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000;157:1429-35.
7. Bschor T, Bergh6fer A, Str6hle A, Kunz D, Adli M, Miiller-Oerlinghausen B, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 2002;22:427-30.
8, de Montigny C. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol 1994;9 (suppl 2):31-5.
9. Bauer M, D6pfiner S. Lithium augmentation in treatment-resistant depression - a meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999;19:427-34.
10. Joffe RT, Sokolov STH. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 1994;8:45-63.
11. Hendrick V, Altshuler L, Whybrow P. Psychoneuroendocrinology of mood disorders. The hypothalamic-pituitarythyroid axis. Psychiatr Clin North Ain 1998;21:277-92.
12. Marangell LB, Callahan AM. Mood disorders and the thyroid axis. Curr Opinion Psychiatry 1998;11:67-70.
13. Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001;2:57-67.
14. Cole DP, Thase ME, Mallinger
JC, Luther JF, Kupfer DJ, et al. Slower treatment response in bipolar
predicted by lower pretreatment thyroid function. Ann J
15. Joffe RT, Levitt AJ, Bagby RM, MacDonald C, Singer W. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993;163:574-8.
16. Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neu ropsychobiology 1999;40:134-9.
17. Sch6pf J, Lemarchand T. Lithium addition in endogenous depressions resistant to tricyclic antidepressants or related drugs: relation to the status of the pituitary-thyroid axis. Pharmacopsychiatry 1994;27:198-201.
18. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M. Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 2001,64:261-5.
19. Bschor T, Adli M, Baethge C, Eichmann U, Ising M, Uhr M, et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 2002;27:470-8.
20. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M. SKID-I. Strrdcturiertes Klinisches Interviezo fiir DSM-IV. Achse I: Psychische Storungen. G6ttingen: Hogrefe; 1997.
21. Adli M, Bergh6fer A, Linden M, Helmchen H, Muller-Oerlinghausen B, Mackert A, et al. Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders: results of a two-year observational study. J Clin Psychiatry 2002;63:782-90.
22. Linden M, Helmchen H, Mackert A, Miiller-Oerlinghausen B. Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed inpatients. Pharmacopsychiatry 1994;27(Suppl):51-3.
23. Hamilton M. A rating scale for depression. J Neurol NeurosurY Psychiatry 1960;23:56-62.
24. Baumgartner A, Graf KJ, Kiirten I, Meinhold 1-1. The hypothalamic-pituitary-thyroid axis in psychiatric and healthy subjects: parts 1-4. Psychiatr Res 1988;24:271-332.
25. Kirkegaard C, Faber J. Altered serum levels of thyroxine, triiodothyronines and diiodothyronines in endogenous depression. Acta Endocrinol (Copenh) 1981;96:199-207.
26. Roy-Byrne PP, Joffe RT, Uhde TW, Post RM. Carbamazepine and thyroid function in affectivcly ill patients. Clinical and theoretical implications. Arch Gen Psychiatry 1984;41:1150-3.
27. Joffe RT, Blank DW, Post RM, Uhde TW. Decreased triiodothyronines in depression: a preliminary report. Biol Psychiatry 1985;20:922-5.
28. Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999;60:249-55.
29. Lazarus JH. The endocrinological effects of lithium. In: Birch NJ, Padgharn C, Hughes MS, editors. Lithium in medicine and biology. Lancashire (UK): Marius Press; 1993. p. 127-31.
30. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998;8:909-13.
31. Myers DH, Carter RA, Burns BH, Armond A, Hussain SB, Chengapa VK. A prospective study of the effects of lithium on thyroid function and on the prevalence of antithyroid antibodies. Psychol Med 1985;15:55-61.
32. Bocchetta A, Bernardi F, Pedditzi M, Loviselli A, Velhrzzi F, Martino E, et al. Thyroid abnormalities during lithium treatment. Acta Psychiatr Scand 1991;83:193-8.
33. Lombardi G, Panza N, Biondi B, Di Lorenzo L, Lupoli G, Muscettola G, of al. Effects of lithium treatment on hypothalamic-pituitary-thyroid axis: a longitudinal study. J Endocrinol Invest 1993;16:259-63.
34. Frye MA, Denicoff KID, Bryan AL, Smith-Jackson EE, Ali SO, Luckenbaugh D, et al. Association between lower serum-free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 1999;156:1909-14.
35. Grof E, Grof P, Brown GM, Downie S. Lithium effects on neuroendocrine function. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:541-6.
36. Perrild H, Hegedues L, Among K. Sex related goitrogenic effect of lithium carbonate in healthy young subjects. Acta Endocrinologica 1984;106:203-8.
37. Gyulai L, Bauer M, Bauer MS,
F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid
bipolar disorder after lithium challenge. Biol Psychiatry. In press.